The medical burden of heart failure (HF) has spurred interest in clinicians and scientists to develop therapies to restore the function of a failing heart. To advance this agenda, the National Heart, Lung, and Blood Institute (NHLBI) convened a Working Group of experts from June 2 to 3, 2016, in Bethesda, Maryland, to develop NHLBI recommendations aimed at advancing the science of cardiac recovery in the setting of mechanical circulatory support (MCS). MCS devices effectively reduce volume and pressure overload that drives the cycle of progressive myocardial dysfunction, thereby triggering structural and functional reverse remodeling. Research in this field could be innovative in many ways, and the Working Group specifically discussed opportunities associated with genome-phenome systems biology approaches; genetic epidemiology; bioinformatics and precision medicine at the population level; advanced imaging modalities, including molecular and metabolic imaging; and the development of minimally invasive surgical and percutaneous bioengineering approaches. These new avenues of investigations could lead to new treatments that target phylogenetically conserved pathways involved in cardiac reparative mechanisms. A central point that emerged from the NHLBI Working Group meeting was that the lessons learned from the MCS investigational setting can be extrapolated to the broader HF population. With the precedents set by the significant effect of studies of other well-controlled and tractable subsets on larger populations, such as the genetic work in both cancer and cardiovascular disease, the work to improve our understanding of cardiac recovery and resilience in MCS patients could be transformational for the greater HF population. (J Am Coll Cardiol Basic Trans Science 2017;-:---)
T he enormous medical burden of heart failure (HF) (1) combined with the scientific challenge to defy biological limits, has spurred interest in clinicians and scientists to restore the function of a failing heart. To advance this agenda, the National Heart, Lung, and Blood Institute (NHLBI) With advanced stages of the disease, clinical experience suggests the notion that chronic mechanical unloading of the heart with ventricular assist devices (VADs) can favorably influence the complex process of reverse cardiac remodeling, such that patients placed on long-term MCS can achieve variable degrees of improvement in the structure and function of the native heart along with reversal of the systemic HF phenotype (4-6).
Excess pressure and volume load drives the cycle of progressive myocardial dysfunction and cardiac remodeling in chronic HF (7) . VADs provide significant volume and pressure unloading and increased cardiac output, which allows a reversal of stressrelated compensatory responses of the overloaded myocardium. As a result, some patients placed on long-term MCS demonstrate reverse cardiac remodeling with restoration of cardiac function, permitting weaning from the MCS device. Table 1 As depicted in Figure 1 , results from such studies could lead to rational therapeutic approaches to facilitate cardiac recovery in the various etiologies and stages of HF.
The NHLBI Working Group identified a critical shortcoming in the field of cardiac recovery with MCS in that most studies to date have failed to correlate functional outcomes with molecular, cellular, or histological findings (4-6). As a result, these earlier studies provide limited information on whether
NHLBI Myocardial Recovery Working Group *"Cardiac recovery" was defined in all studies but the Utah Cardiac Recovery study as LVAD explantation due to cardiac functional and structural improvement (degree of improvement and specific criteria varied between studies). In the Utah Cardiac Recovery study (11), "cardiac recovery" was defined as post-LVAD left ventricular ejection fraction $40% in at least 2 consecutive turn-down echocardiograms and no LVEF <40% at later time points (independently of whether the device was eventually explanted). Despite the heterogeneity in the study design, it appears that most programs (Berlin, U.S. LVAD Working Group, Montefiore, Gothenburg, Vancouver, and Utah groups) identified significant cardiac functional and structural improvement in 15% to 25% of NICM and 4% to 5% of ICM. †The U.S. IMAC (Intervention in Myocarditis and Acute Cardiomyopathy) study group (17) included only patients with "recent onset cardiomyopathy."
HF ¼ heart failure; ICM ¼ ischemic cardiomyopathy; NICM ¼ nonischemic cardiomyopathy; LVAD ¼ left ventricular assist device; N/A ¼ not applicable.
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Drakos et al. Finally, the Working Group also developed the following working definition of cardiac recovery:
MCS MCS MC MCS MCS MC MCS MCS MCS MCS MCS MCS MCS MCS CS MCS CS MCS MCS MCS MCS MCS MCS MCS MCS MCS CS CS MC MCS MCS MCS MCS MCS MCS C MC C CS C MC MCS M MCS CS M MCS MCS MCS
"A reversal of the pathological state of the myocardium with significant improvement in cardiac structure and function sufficient to achieve a sustained remission from recurrent heart failure events."
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